Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIN2B | Q13224 | 14/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.46 |
| ▸ | NPC1 | O15118 | 2/20 | 0.46 |
| ▸ | RAB9A | P51151 | 2/20 | 0.46 |
| ▸ | NAPEPLD | Q6IQ20 | 1/20 | 0.45 |
| ▸ | CYP2D6 | P10635 | 4/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 4/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12745291 | 0.91 | GRIN2B (0.56) | GRIN2BSMN1; SMN2NPC1RAB9ANAPEPLD | |
| SCHEMBL12745281 | 0.90 | GRIN2B (0.55) | GRIN2BSMN1; SMN2NPC1RAB9ANAPEPLD | |
| SCHEMBL1461684 | 0.82 | GRIN2B (0.55) | GRIN2BSMN1; SMN2NPC1RAB9ANAPEPLD | |
| SCHEMBL12827320 | 0.81 | L3MBTL1 (0.43) | SMN1; SMN2NPC1RAB9ANAPEPLDCYP2C19 | |
| SCHEMBL12826870 | 0.78 | HSD11B1 (0.45) | GRIN2BCYP2D6CYP2C9 | |
| SCHEMBL21876932 | 0.77 | TMEM97 (0.47) | SMN1; SMN2NPC1RAB9ACYP2C19MEN1 | |
| SCHEMBL21776298 | 0.77 | SMN1; SMN2 (0.67) | GRIN2BSMN1; SMN2NPC1RAB9ACYP2D6 | |
| SCHEMBL25382940 | 0.76 | GRIN2B (0.52) | GRIN2BSMN1; SMN2NPC1RAB9ACYP2D6 | |
| SCHEMBL12745126 | 0.76 | ENPP2 (0.50) | GRIN2BSMN1; SMN2NPC1RAB9ANAPEPLD | |
| SCHEMBL1462911 | 0.73 | SMN1; SMN2 (0.47) | GRIN2BSMN1; SMN2NPC1RAB9ANAPEPLD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110071289-A1 | AMINOPYRAZOLE AMIDE DERIVATIVE | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2011-03-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110071289-A1 | AMINOPYRAZOLE AMIDE DERIVATIVE | ARGLU1, ARG1, CNKSR1 | GRIN2B 3519/4885SMN1; SMN2 4234/4885NPC1 4064/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.